Full-Time

Senior Scientist

Protein Sciences and Antibody Discovery

Confirmed live in the last 24 hours

Adaptive Biotechnologies

Adaptive Biotechnologies

501-1,000 employees

Decodes immune cell receptors for diagnostics

Biotechnology
Healthcare

Compensation Overview

$113.5k - $170.3kAnnually

+ Equity Grant + Bonus

Senior, Expert

No H1B Sponsorship

Seattle, WA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Chemistry, Molecular Biology, Immunology, or related fields with 5+ years of experience, or a Master’s degree with 13+ years of experience.
  • Strong scientific background in antibody discovery using immunization or display platforms.
  • Proficiency in protein design for immunization campaigns and antibody screening/engineering.
  • Expertise in recombinant protein expression systems, including mammalian, insect, and E. coli.
  • Skilled in recombinant protein and antibody purification using the AKTA system (affinity, SEC, ion exchange).
  • Experience with protein analytics (protein kinetics, epitope binning, stability) using BLI, HPLC, and DLS.
  • Competency in molecular biology techniques such as cloning, DNA and RNA extraction, and B/T cell sequencing.
  • Familiarity with molecular biology software (e.g., Geneious), molecular modeling (e.g., AlphaFold, Rosetta, Modeller), molecular visualization (e.g., PyMol), and data graphing (e.g., Prism).
  • Ability to work in a fast-paced, collaborative, cross-functional environment.
  • Experience managing work with CROs.
  • Excellent technical presentation and writing skills. Maintaining thorough records in an electronic lab notebook (e.g., Benchling).
  • Ability to work independently, adapt to shifting priorities, manage multiple tasks with short lead times, and identify and implement solutions.
Responsibilities
  • Design and purify high-quality recombinant proteins to support Antibody and TCR Discovery.
  • Conduct hands-on lab research for biophysical characterization of antibodies and other proteins.
  • Engage in antibody discovery and engineering using phage display.
  • Support Protein Sciences needs across Antibody Discovery programs and other cross-functional projects.
  • Provide strategic input into evaluating novel technologies and therapeutic modalities.
Adaptive Biotechnologies

Adaptive Biotechnologies

View

Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand how the immune system reacts to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to leverage immune system data to advance healthcare and develop effective therapies for various diseases.

Company Stage

IPO

Total Funding

$395.8M

Headquarters

Seattle, Washington

Founded

2009

Growth & Insights
Headcount

6 month growth

-5%

1 year growth

-11%

2 year growth

-15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for personalized medicine boosts need for Adaptive's diagnostic tools.
  • AI integration enhances accuracy and speed of Adaptive's genetic analysis offerings.
  • Collaborations with pharmaceutical companies expand clonoSEQ® assay applications.

What critics are saying

  • Competition from companies like EndoSound may impact Adaptive's market share.
  • New startups focusing on AI may divert investment from traditional biotech firms.
  • Technical hurdles in clonoSEQ® and Epic integration could delay implementation.

What makes Adaptive Biotechnologies unique

  • Adaptive Biotechnologies leverages immune system data for advanced diagnostics and treatments.
  • Their clonoSEQ® assay is FDA-authorized for minimal residual disease detection in blood cancers.
  • The ImmuneRACE study enhances understanding of immune responses to COVID-19.

Help us improve and share your feedback! Did you find this helpful?